Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Derazantinib: an investigational drug for the treatment of cholangiocarcinoma.

Expert opinion on investigational drugs - 1 Nov 2021

Braun Stephan, McSheehy Paul, Litherland Karine, McKernan Phil, Forster-Gross Nicole, Bachmann Felix, El-Shemerly Mahmoud, Dimova-Dobreva Miryana, Polyakova Inessa, Häckl Manuel, Zhou Ping, Lane Heidi, Kellenberger Laurenz, Engelhardt Marc

Abstract excerpt

INTRODUCTION: This review evaluates the clinical role of fibroblast growth factor receptor 2 (FGFR2) inhibition with derazantinib in patients with intrahepatic cholangiocarcinoma (iCCA) harboring actionable oncogenic FGFR2 fusions/rearrangements, mutations and amplifications. FGFR inhibitors such as derazantinib are currently being evaluated to address the unmet medical need of patients with previously treated,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aniline Compounds
Share to Bile Duct Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholangiocarcinoma

Share to Drugs, Investigational

Share to Gene Rearrangement

Share to Protein Kinase Inhibitors

Share to Quinazolines

Share to Receptor, Fibroblast Growth Factor, Type 2

Source

Identifiers

PMID: 34698609
DOI: 10.1080/13543784.2021.1995355

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Derazantinib: an investigational drug for the treatment of cholangiocarcinoma.PMID 34698609Read ↗

FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma.Semantic proximity Read ↗

Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy.Semantic proximity Read ↗

FGFR2 Inhibition in Cholangiocarcinoma.Semantic proximity Read ↗

Past, present, and future of FGFR inhibitors in cholangiocarcinoma: from biological mechanisms to clinical applications.Semantic proximity Read ↗

Molecular biology of cholangiocarcinoma and its implications for targeted therapy in patient management.Semantic proximity Read ↗

Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial.Semantic proximity Read ↗

Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma.Semantic proximity Read ↗

Molecular Pathogenesis of Cholangiocarcinoma: Implications for Disease Classification and Therapy.Semantic proximity Read ↗

Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinomaSemantic proximity Read ↗

Evolution of Treatment in Advanced Cholangiocarcinoma: Old and New towards Precision Oncology.Semantic proximity Read ↗

Molecular Profile of Intrahepatic CholangiocarcinomaSemantic proximity Read ↗

Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.